PT-141 (Bremelanotide): History and Development

From Tanning Peptides to Sexual Medicine: The Accidental Discovery

Bremelanotide's story begins not in a sexual medicine lab but in dermatology research. In the early 1990s, researchers at the University of Arizona, led by Mac Hadley and Victor Hruby, were developing synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) to induce skin pigmentation without UV exposure. Their cyclic heptapeptide, Melanotan II, did trigger tanning in human subjects. It also triggered something unexpected.

During a Phase I study, a male volunteer self-administered a dose roughly double the protocol target and experienced a prolonged, spontaneous erection lasting eight hours. That single adverse event report shifted the entire research trajectory. The Hruby lab recognized that melanocortin signaling might act centrally on sexual arousal pathways, distinct from the peripheral vascular mechanism of phosphodiesterase-5 inhibitors like sildenafil.

Melanotan II, however, posed problems for drug development. It activated multiple melanocortin receptor subtypes non-selectively and carried a risk of nausea and cardiovascular effects at doses needed for sexual function. Palatin Technologies, a New Jersey-based pharmaceutical company that licensed the University of Arizona's melanocortin work in 1996, set out to engineer a more targeted molecule. The result was PT-141, a cyclic lactam peptide that retained Melanotan II's core pharmacophore but eliminated the linear tail responsible for much of its off-target binding.

How Bremelanotide Works: The Melanocortin Mechanism

PT-141 activates melanocortin-4 receptors (MC4R) and, to a lesser extent, melanocortin-3 receptors (MC3R) in the central nervous system. This is the critical distinction between bremelanotide and every other approved sexual dysfunction drug. Sildenafil, tadalafil, and other PDE5 inhibitors work peripherally on penile blood vessels. Flibanserin acts on serotonin receptors. Bremelanotide acts on melanocortin circuits in the hypothalamus and limbic system that regulate appetitive sexual behavior.

MC4R is expressed in the medial preoptic area, the ventromedial hypothalamus, and the amygdala. These regions are directly involved in the motivational and arousal components of sexual response. When bremelanotide binds MC4R, downstream signaling increases activity in pathways associated with dopamine and oxytocin release [1]. The effect is not mechanical arousal per se, but an increase in sexual desire and the motivation to initiate sexual activity.

Animal data illustrate this distinction clearly. In a 2004 study by Pfaus et al. using female rat models, PT-141 administration increased solicitation behaviors (hopping and darting) without altering lordosis reflex or peripheral genital engorgement. The drug changed the animals' appetitive approach to mating, not the physical capacity for it. That behavioral specificity made it especially relevant for HSDD, a condition defined by absent or reduced desire rather than impaired genital response.

Preclinical and Early Clinical Development (1996-2008)

Palatin Technologies filed its first investigational new drug (IND) application for PT-141 in 2001. Early clinical work initially focused on male erectile dysfunction, where bremelanotide was administered as a nasal spray.

Phase II trials in men with ED produced mixed but interesting results. A 2005 study by Diamond et al. demonstrated that intranasal PT-141 at 7 mg and 20 mg doses produced statistically significant erectile responses compared with placebo in men who had failed sildenafil. The drug was activating an entirely different pathway from PDE5 inhibitors, and some non-responders to Viagra responded to PT-141.

Then the program hit a wall. In May 2008, the FDA placed a clinical hold on the intranasal PT-141 program after Phase III data showed dose-dependent blood pressure elevations and the nasal delivery system produced inconsistent bioavailability. Palatin's stock dropped sharply. The ED indication appeared dead.

But two decisions saved the molecule. First, Palatin pivoted from erectile dysfunction to HSDD in premenopausal women, a population with no FDA-approved pharmacotherapy at that time (flibanserin would not gain approval until 2015). Second, they switched from intranasal to subcutaneous injection, which gave predictable pharmacokinetics and allowed lower, more consistent dosing.

The RECONNECT Trials: Phase III Evidence

The key evidence for FDA approval came from the RECONNECT program, consisting of two identically designed, randomized, double-blind, placebo-controlled Phase III trials. Published in Obstetrics & Gynecology in 2019, the studies enrolled a combined 1,247 premenopausal women diagnosed with HSDD [2].

Participants self-administered bremelanotide 1.75 mg subcutaneously as needed, approximately 45 minutes before anticipated sexual activity. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score over 24 weeks.

Results showed statistically significant improvements on both co-primary endpoints. In Study 301, the FSDS-DAO Item 13 score decreased by -0.7 points versus placebo (P<0.001). FSFI desire domain scores increased by approximately 0.5 points more than placebo (P<0.001). Study 302 replicated these findings with comparable effect sizes. Pooled responder analysis showed 50% of bremelanotide patients reported meaningful improvement versus 36% with placebo [2].

Those numbers require context. Effect sizes in HSDD trials are modest across all approved agents. The RECONNECT results were roughly comparable to flibanserin's BEGONIA and DAISY trials on desire endpoints [3]. The clinical debate is not whether the effect is real but whether the magnitude justifies injection. The FDA's advisory committee voted 14-10 in favor of approval, with dissenting members citing the modest effect size and a 40% nausea rate.

FDA Approval and the Vyleesi Label

On June 21, 2019, the FDA approved bremelanotide injection under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women [4]. AMAG Pharmaceuticals, which had licensed commercial rights from Palatin in 2017 for $60 million upfront plus milestones, handled the U.S. launch.

Key label restrictions reflected the drug's safety profile:

The prescribing information limits use to no more than one dose per 24 hours and no more than 8 doses per month [4]. This dosing cap was driven by the transient blood pressure elevations observed in clinical trials, specifically a mean increase of 6 mmHg systolic and 3 mmHg diastolic that peaked at 2-4 hours post-dose and resolved within 12 hours.

The most common adverse reactions in clinical trials were nausea (40.0%), flushing (20.3%), injection-site reactions (13.2%), and headache (11.3%). Nausea was the primary reason for discontinuation, occurring in roughly 7% of bremelanotide-treated patients. The nausea was generally transient, peaking at first use and diminishing with repeated administrations in most patients [2].

Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, and the label carries a warning about its potential to decrease blood pressure in patients on naltrexone or other opioid antagonists.

The Commercial Trajectory and Post-Approval Shifts

Vyleesi's commercial performance has been modest. AMAG launched the drug in September 2019 at a list price of approximately $900 per auto-injector kit (four single-use doses). Within months, prescriptions fell below expectations. High out-of-pocket costs, the nausea profile, the injection route, and limited direct-to-consumer marketing all contributed.

AMAG Pharmaceuticals was acquired by Covis Pharma in November 2020 for $650 million. Covis subsequently managed the Vyleesi commercial portfolio with a leaner marketing footprint. Meanwhile, Palatin Technologies continued to develop next-generation melanocortin compounds. Their oral MC4R agonist program, PL-8177, initially targeted inflammatory bowel disease rather than sexual dysfunction, though oral bioavailability of melanocortin agonists remained a major pharmaceutical chemistry challenge.

The off-label market tells a different story. PT-141 (as compounded bremelanotide) has seen significant use in men's health and anti-aging clinics for erectile dysfunction, often prescribed alongside PDE5 inhibitors for patients with partial responses. This off-label use occurs outside Vyleesi's approved indication and dosing, and the Endocrine Society has not issued formal guidelines on melanocortin agonists for male sexual dysfunction. Clinicians using it off-label for men generally cite the Diamond et al. Phase II data and the theoretical advantage of a central mechanism in psychogenic ED.

The Broader Melanocortin Research Program

Bremelanotide's development contributed significantly to the scientific understanding of melanocortin signaling in human sexual function. Before the University of Arizona's tanning peptide work, MC4R was primarily studied in the context of energy homeostasis and obesity. Loss-of-function mutations in MC4R are the most common monogenic cause of severe obesity, affecting roughly 2-5% of individuals with BMI >40 [5].

The discovery that MC4R activation also modulates sexual desire opened parallel research tracks. Setmelanotide, another MC4R agonist developed by Rhythm Pharmaceuticals, received FDA approval in 2020 for rare genetic obesity syndromes caused by POMC, PCSK1, or LEPR deficiency. Setmelanotide was designed to avoid the pro-sexual effects of bremelanotide by targeting MC4R in a different conformational context, though some patients in clinical trials did report changes in sexual function as a secondary effect [6].

The melanocortin system's dual role in feeding and reproduction makes evolutionary sense. Both functions are regulated by hypothalamic circuits that integrate energy status with reproductive behavior. MC4R sits at the intersection. This molecular crosstalk explains why Melanotan II and its derivatives affect both appetite and desire, and why designing selective modulators for one pathway without the other remains difficult.

Where PT-141 Development Stands Now

As of 2025, Palatin Technologies holds an active pipeline of melanocortin-based therapeutics targeting inflammation, obesity, and sexual dysfunction through oral and alternative delivery platforms [7]. The core challenge is achieving oral bioavailability. Cyclic peptides like bremelanotide are degraded by gastrointestinal proteases, which is why the approved product requires subcutaneous injection.

Several academic groups are investigating MC4R positive allosteric modulators (PAMs) that could potentiate endogenous melanocortin signaling rather than directly activating the receptor. This approach might produce a more physiologic effect profile with fewer adverse effects like nausea. No MC4R PAM has entered clinical trials as of this writing.

The compounding pharmacy sector continues to supply PT-141 peptide for off-label clinical use, though the FDA's 2023-2024 enforcement actions on peptide compounding (primarily targeting semaglutide and tirzepatide) have raised questions about the future regulatory status of compounded bremelanotide. Clinicians prescribing compounded PT-141 should monitor evolving FDA guidance on compounded peptides.

The 1.75 mg subcutaneous dose approved under the Vyleesi label remains the only FDA-sanctioned formulation and dose for bremelanotide, restricted to HSDD in premenopausal women, with a maximum of 8 doses per calendar month.